Navigation Links
Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
Date:9/2/2008

Phase II Study Meets Primary Bone Mineral Density and Secondary Efficacy

Endpoints Company to Host Conference Call and Webcast Wednesday, September 3rd at

8:30 am ET / 5:30 am PT

SAN DIEGO, Sept. 2 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced positive safety and efficacy results from its third Phase II clinical trial using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis. The PETAL study enrolled 252 patients, with a confirmed diagnosis of endometriosis, into three treatment groups; elagolix 150 mg once daily, elagolix 75 mg twice daily, or depo-subQ provera 104(TM) (DMPA) for six months of treatment.

The primary endpoint for the PETAL study was the percent change from baseline in mean bone mineral density (BMD) at Month 6 measured via dual energy X-ray absorptiometry (DXA). Pursuant to discussion with the FDA, the pre-specified statistical analysis plan sought to demonstrate that at Month 6, the lower bound of the 95% confidence interval did not exceed a -2.2% change in BMD from baseline. In women randomized to elagolix 150 mg once daily, the mean percent change from baseline at Month 6 was -0.11% for the spine (lower bound -0.70%) and -0.47% for the femur (lower bound -0.96%). The mean percent change from baseline at Month 6 for the elagolix 75 mg twice daily dosing arm was -1.30% for the spine (lower bound -1.86%) and -0.99% for the femur (lower bound -1.46%).

"The PETAL study demonstrates that elagolix did not induce significant bone loss over a six month treatment of patients with endometriosis, while providing both rap
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
2. Neurocrine Biosciences Reports First Quarter 2008 Results
3. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
4. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
5. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
6. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
7. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
10. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
11. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Calif. , Oct. 1, 2014 /PRNewswire/ ... ), a clinical-stage biopharmaceutical company focused on ... positive results from its 371 patient Phase ... with constipation-predominant irritable bowel syndrome (IBS-C).  Results ... clinically meaningful improvement in IBS-C symptoms for ...
(Date:10/1/2014)... October 1, 2014 Sophia Genetics, ... Sequencing (NGS) data analysis, today launches a unique CFTR ... analysis in a single NGS experiment. The CE-IVD marked ... of variants in a single NGS experiment with clinical ... not been possible to simultaneously analyse all relevant CFTR ...
(Date:9/30/2014)... , Sept. 30, 2014  Wrightington, Wigan ... Allscripts (NASDAQ: MDRX ) are delighted to ... as WWL,s new health information system. The system will ... completely transform the way WWL delivers healthcare in the ... a demonstrated record of on-time and on-budget system implementations ...
Breaking Medicine Technology:Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 5Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 6Sophia Genetics Launches Full CFTR Analysis in Single Clinical Grade NGS Experiment 2Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 2Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 3Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 4
... /PRNewswire-Asia-FirstCall/ -- China Nepstar Chain Drugstore Ltd. (NYSE: ... largest drugstore chain in China based on the number ... will report its third quarter 2010 financial results on ... The Company will host a conference call, to ...
... Tibotec Announced Week 24 Interim Results From Phase... -- HUDDINGE, Sweden, November 1, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so ...
Cached Medicine Technology:China Nepstar Chain Drugstore to Report Third Quarter 2010 Financial Results on November 17, 2010 2Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD 2Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD 3Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD 4Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD 5Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD 6Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD 7Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD 8Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD 9Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD 10Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD 11Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD 12Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD 13
(Date:10/1/2014)... California (PRWEB) October 01, 2014 ... to benefit a very special cause. The campaign—“Buy ... support for Paws for Veterans, a nonprofit organization ... while also rescuing shelter dogs that would otherwise ... of featured products will support monthly donations of ...
(Date:10/1/2014)... October 01, 2014 Woodland Hills ... to a group of dental specialists who treat full ... Spain city of Oviedo. Dr. Reshad of the Anacapa ... with clients on two continents, will give a full-day ... full mouth reconstruction. , “These specialists want to improve ...
(Date:10/1/2014)... CA (PRWEB) October 01, 2014 Today ... the Anacapa Dental Art Institute in Oxnard and Woodland ... Bangalore providing full mouth rehabilitation training. , “Speaking to ... of these transformative procedures to get the help and ... rehabilitation may involve repairing previous dental work, providing cosmetic ...
(Date:10/1/2014)... DC (PRWEB) October 01, 2014 Generic ... all retail generics increasing in price in the last ... Services, Inc.’s (AIS) Drug Benefit News (DBN) interviewed a ... trend means for pharmacies and health plans. , ... with rising generic acquisition costs, these cost increases squeeze ...
(Date:10/1/2014)... Madison, Wi (PRWEB) October 01, 2014 ... sales of UP4 WOMEN’S probiotic to The National Network ... month of October. This organization was chosen through nationwide ... UP4’s website and social media outlets. , “We ... to receive a portion of every sale of UP4 ...
Breaking Medicine News(10 mins):Health News:Nordic Naturals® Inspires Support for Paws for Veterans -- ‘Buy One Bottle. Help Two Heroes.’ Initiative Kicks Off October 1 2Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 2Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 3Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 4Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 2Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 3Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 4Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 5Health News:Rising Generic Drug Prices Affect Pharmacies, Insurers Alike, Reports AIS Newsletter 2Health News:Rising Generic Drug Prices Affect Pharmacies, Insurers Alike, Reports AIS Newsletter 3Health News:UP4 Probiotics Partners with The National Network to End Domestic Violence 2
... 2008 Use of the drug interferon as a ... disease associated with the hepatitis C virus is ineffective, ... nine other institutions have found in a multicenter study. ... (Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis) Trial, appear ...
... Corporation (NYSE: GTS ) today announced that it ... managed care assets of La Cruz,Azul de Puerto Rico, ... Association to transfer the licensing rights to the Blue Cross ... brands in the US Virgin Islands,to the Company and Triple-S, ...
... Available from NetLearning , ... Clifton ... leading provider of integrated e-learning solutions for healthcare training, compliance, ... pleased to announce the latest major release of the Learning ...
... medication used for high blood pressure does not improve ... results from a large, international study. , The ... Medical Center in key leadership positions, appears in this ... Medicine , published today. , The findings are disappointing ...
... finds , , THURSDAY, Dec. 4 (HealthDay News) -- Reactions ... are rare, and young women can tolerate subsequent doses. ... data after more than 380,000 doses of the Gardasil ... in April 2007. , Gardasil protects against four ...
... of Steven Sabock, a 50-year-old man with bipolar disorder who ... psychiatric institution after he choked on medication -- while, ... has focused attention on the crisis in North Carolina,s mental ... tragic, preventable death of Steven Sabock -- which made headlines ...
Cached Medicine News:Health News:HALT-C researchers: Interferon as long-term treatment for hepatitis C not effective 2Health News:Triple-S Management Corporation Signs Letter of Intent to Acquire Managed Care Portfolio of La Cruz Azul de Puerto Rico, Inc. 2Health News:NetLearning Releases Learning Administrator 7.1 for Online Professional Healthcare Training 2Health News:NetLearning Releases Learning Administrator 7.1 for Online Professional Healthcare Training 3Health News:Study finds treatment fails to improve common form of heart failure 2Health News:Study finds treatment fails to improve common form of heart failure 3Health News:Cervical Cancer Vaccine Well Tolerated 2Health News:Tragedy Focuses Spotlight on Crisis in North Carolina Mental Health System 2
Full Handle Laseredge Implant Blade Knife, 4.0 mm straight. Blade dimension: 15.2 mm x 4.0 mm x 3.0 mm x 1.6 mm....
Full Handle Laseredge Crescent Blade Knife, straight. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Stab Blade Knife, 45 blade. Blade tip dimension: 8.9 mm x 1.9 mm x 1.9 mm....
Full Handle Laseredge Stab Blade Knife, 15 blade. Blade tip dimension: 11.1 mm x 1.5 mm x 5.7 mm....
Medicine Products: